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Background:We explored catalytic antibodies applicable to patients.
Results:Ahuman light chain (22F6) possessing both amidase and nuclease activities and preventing infection of influenza virus
was obtained.
Conclusion: The 22F6 light chain holds a huge potential as a new drug for patient therapies in the future.
Significance: The procedure developed in this study is highly noteworthy for developing new drugs.
Human antibody light chains belonging to subgroup II of
germ line genes were amplified by a seminested PCR technique
using B-lymphocytes taken from a human adult infected with
influenza virus. Each gene of the human light chains was trans-
ferred into the Escherichia coli system. The recovered light
chain was highly purified using a two-step purification system.
Light chain 22F6 showed interesting catalytic features. The light
chain cleaved a peptide bond of synthetic peptidyl-4-methyl-
coumaryl-7-amide (MCA) substrates, such as QAR-MCA and
EAR-MCA, indicating amidase activity. It also hydrolyzed a
phosphodiester bond of both DNA and RNA. From the analysis
of amino acid sequences andmolecularmodeling, the 22F6 light
chain possesses two kinds of active sites as amidase andnuclease
in close distances. The 22F6 catalytic light chain could suppress
the infection of influenza virus type A (H1N1) of Madin-Darby
canine kidney cells in an in vitro assay. In addition, the catalytic
light chain clearly inhibited the infection of the influenza virus
of BALB/c mice via nasal administration in an in vivo assay. In
the experiment, the titer in the serum of the mice coinfected
with the 22F6 light chain and H1N1 virus became considerably
lowered comparedwith that of 22F6-non-coinfectedmice. Note
that the catalytic light chain was prepared from human periph-
eral lymphocyte andplays an important role in preventing infec-
tion by influenza virus. Considering the fact that the human
light chain did not show any acute toxicity for mice, our proce-
dure developed in this studymust be unique and noteworthy for
developing new drugs.
Natural type antibodies and their subunits (light and heavy
chains) possessing catalytic features have been extensively
studied for the past 2 decades. As a result, some unique catalytic
antibodies have been successfully produced from the viewpoint
of various reactivities. Catalytic antibodies, such as vasoactive
intestinal peptide (1), DNA (2), HIV gp41 (3), HIV gp120 (4),
and factor VIII (5), exhibited degradation abilities against anti-
gens, as reported by Paul et al. (4), Gabibov and co-workers (2),
Uda and co-workers (3), and Kaveri and co-workers (7).
Regarding the preparation of a catalytic antibody, Paul et al. (4)
proposed a uniquemethod named “covalently reactive analog,”
which derived a catalytic antibody against HIV (6). The physi-
ological role with respect to autoimmunity in humans was clar-
ified by Kaveri and co-workers (7). In the case of Ponomarenko
et al. (8), they obtained reactive autoantibodies (from the sera of
humans with multiple sclerosis) to specifically cleave myelin
basic protein but not other proteins. Nevinsky and co-workers
(9, 10) purified catalytic antibodies cleaving DNA and RNA
from the autoimmune diseases, such as systematic lupus ery-
thematous, multiple sclerosis, Sjogren syndrome, etc. The
patients bearing autoimmune diseases frequently have
nuclease-like catalytic antibodies.
Recently, a unique catalytic antibody A17 named a “reacti-
body” was prepared by Smirnov et al. (11) by employing an
innovative idea and technique. It could cleave paraoxon and
possesses an unusual deep cavity at the interface of VL and VH.
An antibody light chain that is a subunit of the parent anti-
body exhibited interesting catalytic features as a peptidase
and/or proteinase capable of cleaving vasoactive intestinal pep-
tide (1), prothrombine (12), chemokine receptor CCR-5 (13),
urease of Helicobacter pylori (14), etc. Today, meaningful
results of in vitro as well as in vivo assays are very important to
medicinal applications in the near future. The catalytic light
chain by Hifumi and co-workers (13) suppressed a number of
H. pylori infecting the stomachs ofmice. They also reported the
good efficacy of a mouse-type catalytic antibody heavy chain in
suppressing infection of influenza virus type A in an in vitro
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assay (15). In addition, they have recently developed a human
type catalytic light chain capable of increasing the survival rate
of suckling mice infected with the rabies virus in an in vivo
experiment (16).
The ultimate goal of catalytic antibody research is to develop
new patient therapies that utilize the advantages offered by
human catalytic antibodies. Through 2 decades of study of nat-
ural type catalytic antibodies as mentioned above, that goal is
coming to fruition, because such antibodies are close to actual
utilization. In this study, we prepared some antibody light chain
genes taken from human lymphocytes, followed by expression
of the genes inEscherichia coli. The human antibody light chain
22F6, of 20 other light chains, showednot only catalytic features
but also a substantial effect on suppression of influenza virus
infection in both in vitro and in vivo assays. The unique catalytic
light chain 22F6 found in this study may open up applicable
uses of the catalytic antibodies in the near future.
MATERIALS AND METHODS
Amplification of DNA Fragments Encoding Light Chains from
Germ Line Genes of Subgroup II
We obtained 100 ml of peripheral blood from a healthy vol-
unteer immunized by previous infections of influenza viruses.
Peripheral blood lymphocytes were harvested using a Ficoll-
Paque (GE Healthcare) gradient, and five vials of 1.0  107
cells/ml were stored in liquid nitrogen. Total RNA was
extracted from 3.0 107 cells using an RNA isolation kit (Strat-
agene, La Jolla, CA). cDNA was synthesized by reverse tran-
scription-PCR using a total RNA template using oligo(dT) as a
primer (ThermoScript RT-PCR system; Invitrogen). DNA frag-
ments encoding human light chains were amplified from the
cDNA by PCR using four primers separately as a forward
primer (5-cacctagGATATTGTGATGACCCAG-3) and one
reverse primer (5-ACACTCTCCCCTGTTGAAGCTCTTT-
GTG-3) (Table 1) including a direct insert to the TOPO site
and a start codon. The PCR occurred under the following incu-
bation conditions: 5 min at 95 °C, 35 cycles of 15 s at 95 °C, 50 s
at 54 °C for annealing, and 90 s at 72 °C for extension.
The amplified DNA fragments were separated by 3% agarose
gel electrophoresis. Fragments of the expected size (660 bp)
were extracted using a QIAquick gel extraction kit (Qiagen,
Valencia, CA). Purified PCR products were directly ligated to
pET TOPO vector (Invitrogen), and the vectors were trans-
formed into TOP10 cells continuously using a Champion
pET101 directional TOPO expression kit (Invitrogen). After
propagation of the vectors in the TOP10 cells, the inserted
pET21 (b) vector was repurified and transformed into
BL21 Star (DE3) for expression of light chains belonging to
subgroup II.
Sequencing and Molecular Modeling
The 22F6 clonewas sequencedwith theABI automatedDNA
sequencer model 3100 (Applied Biosystems), using the univer-
sal primer of a T7 promoter. The software GENETIX, version 8
(GENETIX, Tokyo, Japan), was used for sequence analysis and
deduction of amino acid sequences. The nucleotide sequence is
registered in DDBJ/EMBL/GenBank (accession number:
AB723624).
Computational analyses of the antibody structures were per-
formed using the deduced VL amino acid sequences on a work
station (Octane 2; Silicon Graphics, Crafton, PA) running AbM
software (OxfordMolecular, Oxford, UK) used to buildmodels of
three-dimensional molecules. The resulting Protein Data Bank
data were applied tominimize the total energy by using DS-Mod-
eling (Accelrys Software, San Diego, CA). This software uses the
CHARMm algorithm for minimizing the energy of a molecule.
Expression and Purification of Light Chain 22F6
pCR-Blunt II TOPO vectors containing DNA fragments
encoding human light chains were digested by restriction
enzymes NcoI and XhoI (New England BioLabs, Beverly, MA).
The resulting DNA fragments were inserted between the same
restriction sites of expression vector pET20b() (Novagen,
Madison, WI). To express light chains, the expression vectors
were transformed into BL21 (DE3) pLysS (Novagen). The trans-
formant was grown at 37 °C in 1 liter of Luria-Bertani medium
containing 100 g/ml ampicillin to an A600 nm of 0.6 and then
incubated with 0.01 mM isopropyl--D-thiogalactopyranoside
(Wako Pure Chemicals, Osaka, Japan) for 20 h at 18 °C.
Cells were harvested by centrifugation (3,500  g, 4 °C, 10
min) and then resuspended in a solution (0.25 M NaCl, 25 mM
Tris-HCl, pH 8.0). The cells were lysed by ultrasonication three
times for 2 min each in an ice bath, followed by centrifugation
(14,000 g, 4 °C, 20min). The expressed human light chainwas
recovered as the supernatant. A soluble fraction from E. coli
was directly applied to nickel-nitrilotriacetic acid column chro-
matography (Takara, Otsu, Japan) equilibrated with 50 mM
sodium phosphate, pH 7.0, containing 300 mM NaCl. The elu-
tion was performed by increasing the concentration of imidaz-
ole from 0 to 300 mM. Fractions containing 31-kDa protein
(corresponding to a human light chain) in SDS-PAGE analysis
were collected, dialyzed against a 50 mM sodium acetate buffer,
pH 5.5, and then purified by cation exchange chromatography
using a column of SP-5PW (Tosoh) with a gradient of NaCl
solution (from 0.2 to 0.7 M).
By this method, a highly purified light chain (99%) was
confirmed by SDS-PAGE with silver staining. No band except
for the light chain was visible to the naked eye; nor could we see
any contamination of proteases coming from E. coli. Protein
concentrations were determined by the Bradfordmethod using
a Lowry method using the DC protein assay kit (Bio-Rad).
Western Blot Analysis
We prepared a lysed virus sample to use in the following
Western blot analysis. Namely, influenza A virus (A/Hiroshima/
37/2001(H1N1)) obtained by egg culture was prepared and
treated with detergent (1% Triton X-100). Then the lysed
virus solution was submitted to an SDS-PAGE experiment
without staining. Next, the proteins were transferred from
the gel onto an Immobilon-P PVDF membrane. The PVDF
membrane was blocked with TBS containing 0.3% skim milk
and 0.05% Tween 20. After being washed with TBS containing
0.05% Tween 20 (TBS-T), the membrane was incubated with
the light chain 22F6 (50.9 g/ml). After washing with TBS-T,
goat anti-human IgG (F(ab)2 labeled with horseradish peroxi-
dase (1:250 dilution; ImmunoPure antibody, lot number
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JG1153174, Thermo Scientific) as a second antibody was
reacted with the membrane for 1 h at room temperature (44).
After four washings with TBS-T, color development was per-
formed using True Blue POD (horseradish peroxidase) sub-
strate (Kirkegaard & Perry Laboratories).
Cleavage Assays
To avoid contamination in cleavage assays, most glassware,
plasticware, and buffer solutions used in this experiment were
sterilized by heating (180 °C, 2 h), autoclaving (121 °C, 20 min),
or filtration through a 0.20-lm sterilized filter as much as pos-
sible. Most of the experiments were performed in a biological
safety cabinet to avoid airborne contamination.
Hydrolysis of Synthetic Peptidyl Substrates (Amidase
Activity)—Cleavage of the amide bond linking AMC to C-ter-
minal amino acid in peptide-AMC substrates (Peptides Inter-
national, Louisville, KY) wasmeasured at 37 °C in PBS contain-
ing 0.05% sodium azide in 96-well plates. Purified light chains
(100 l, 4 M) were mixed with a synthetic substrate (100 l,
100 M). AMC released from the substrate catalyzed by the
light chains was detected by measurement of fluorescence
emission at 470 nm when excited at 360 nm using a microplate
reader (SpectraFluor Plus; Tecan, Maennedorf, Switzerland).
The concentration of the released AMC was estimated using
the fluorescence emission of 50 M AMC as a standard value.
Hydrolysis of Phosphodiester Bond of Plasmid (DNase
Activity)—Prior to the following nuclease activity assay, the
degree of the contamination of DNase from E. coli etc. was
investigated using an in-gel assay, which was performed in
accordance with a previous study (9). As shown in supplemen-
tal Fig. S1, the results concluded that the degree of the contam-
ination is at most about 10%, even if it is the case.
Cleavage of the phosphate bond of plasmid DNA pBR322
was investigated under an incubation time of 0–24 h with the
light chain 22F6. In the solution, the final concentrations of 20
g/ml pBR322 and 50 g/ml light chain 22F6, 10 mM MgCl2, 1
mM EDTA, and 50 mM NaCl were contained in a 25 mM con-
centration of a Tris-HCl buffer (pH 7.5) at a reaction tempera-
ture of 37 °C. The reaction volume was 20 l.
Hydrolysis of Phosphodiester Bond of RNA (RNase Activity)—
Genome RNAs from influenza virus and Noda virus were pre-
pared in accordance with past studies (17, 18). Briefly, virions
were recovered from the banding fraction by ultracentrifuga-
tion. It was dissolved in a 1% Triton X-100 solution containing
10 mg/ml lysolecithin, followed by a 36–60% glycerol density
gradient using ultracentrifugation. Fractions 4, 5, and 6 were
recovered as highly purified RNA of the Noda virus. For the
influenza virus, we failed to prepare influenza RNA because it
was very unstable.
In Vitro Assay
Viruses—The influenza viruses used were A/Hiroshima/37/
2001 (H1N1) andA/Hiroshima/71/2001 (H3N2). These viruses
were grown in MDCK2 cell culturing medium and harvested
and stored as infectious culture fluid at 80 °C until further
use.
Cells—MDCK cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum.
Neutralization Test—Neutralization tests were performed as
follows (19). The monoclonal antibody or antibody light chain
diluted with phosphate-buffered saline (PBS) was mixed with
an equal volume (75 l) of influenza virus diluted with DMEM
adjusted to give a final control count of about 500 pfu/0.2 ml
(2,500 pfu/ml). After incubation for 24 or 48 h at 25 °C, an
infectious virus titer of the mixture was calculated by a plaque
assay. The antibody- or light chain-virus mixture was serially
diluted in 10 steps; 0.2 ml of each mixture was inoculated into
the MDCK cell monolayer, which had been seeded on a 6-well
tissue culture tray (Falcon 3046; BD Biosciences). After adsorp-
tion for 60 min at 34 °C, the inocula in each well were removed
and washed with PBS. The MDCK cells were covered with the
first overlay DMEM containing 1.0% agarose ME (Iwai Chem-
ical Industries, Tokyo, Japan) and 2 mg/ml acetyl trypsin
(Sigma), and the trays were incubated for 2 days in a humidified
5% CO2 incubator at 34 °C. After the incubation, the cells were
covered with the second overlay DMEM (0.005% neutral red in
the first overlay medium). The plaques were counted on the
following day.
In Vivo Assay
After acclimatization of mice (BALB/cN Sea mice, 6 weeks
old, female; KyudouCo. Ltd., Kumamoto, Japan) for 1–2weeks,
25 l (500 pfu/mouse) of a solution including influenza virus
H1N1 (A/Puerto Rico/8/34; PR-8 strain) with or without the
catalytic light chain 22F6was given by nasal administration into
the mice. The mice were carefully examined for 3 weeks (21
days). From 0 to 21 days postinoculation (dpi), the body weight
of each mouse was measured, and the death or survival of the
mouse was also counted. At 7 and 14 dpi, photographs of the
mice were taken.
Assay of Toxicity of Human Light Chains
Acute toxicity tests were performed byAVSSCo. Ltd. (Naga-
saki, Japan). Briefly, BALB/cN Sea female mice (6 weeks old)
purchased from Kyudou Co. Ltd. were also employed in this
experiment. Human light chains were prepared at concentra-
tions of 1.66 and 9.67 mg/ml in PBS.
Single-dose Administration—After acclimatization of the
mice for 1–2 weeks, three kinds of administration were done:
oral, intraperitoneal, and intravenous. For the oral administra-
tion, 0.38–0.41 ml (33.2 mg/kg) was given to each mouse (n 
3mice for each group) using a sondewith a 1-ml syringe (model
number 110515F; Terumo Co. Ltd., Tokyo, Japan). For the
intraperitoneal administration, 0.59–0.63 ml (49.8 mg/kg) was
inoculated intomice (n 6) using a needle (26 gauge 1⁄2, Code
NN-2613S, catalog no. 111021D; Terumo) with the 1-ml
syringe used above. For the intravenous administration, 0.30–
0.32ml (8.3, 24.9, or 145.5mg/kg)was injected intomice (n 3)
using a needle with a 1-ml syringe (26 gauge, catalogue no.
ED-124S; NIPRO, Osaka, Japan).
2 The abbreviations used are: MDCK, Madin-Darby canine kidney; dpi, days
postinoculation; MCA, 4-methyl-coumaryl-7-amide; pAb, polyclonal
antibody.
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Multiple-dose Administration—Multiple doseswere intrave-
nously administered into the BALB/cN Sea femalemice (n 3)
every 7 days using a needle (26 gauge  1⁄2, code NN-2613S,
catalog no. 111021D; Terumo) with a syringe (catalog no.
110515F; Terumo Co. Ltd.). In this case, 0.10–0.11 ml (8.3
mg/kg; inoculation volume 5ml/kg, 1.66mg/ml)was injected
into the mice.
Ethical Committee
This study was performed with the approval of the ethics
committees of Oita University and Nagasaki University.
Statistical Analysis
The statistical significance of differences between experi-
mental groups was determined as follows. For data about the
body weight and organ weight of assayed mice, an F-test was
performed.When the result was equal variance, Student’s t test
was performed. For non-equal variance, an Aspin-Welch t test
was employed to evaluate a significant difference between the
control group and the group treated with the catalytic light
chain. Values of p  0.05 were considered significant.
RESULTS
Expression and Purification
Fig. 1 shows the SDS-PAGE analysis (silver staining) of the
purified light chains under reduced and non-reduced condi-
tions. The 51 and 26 kDa bands under the non-reduced condi-
tion correspond to the light chain dimer andmonomer, respec-
tively. The 43 kDa band is a dimer possessing a different surface
charge from that of 51-kDa dimer. Under the reduced condi-
tion, only the 31 kDa band corresponding to the monomeric
light chain was observed, and no other bands were detected.
The 51 and 26 kDa bands and the 31 kDa band were confirmed
as a human antibody light chain byWestern blot analysis (data
not shown). The light chain underwent N-terminal amino acid
sequence analysis. The sequence was identified as MDIVM,
indicating that post-translational signal peptide removal
occurred correctly. We could obtain over 10 mg of highly puri-
fied 22F6 light chain from a 1-liter scale culture.
Molecular Modeling
The determined nucleotide sequence was registered in
DDBJ/EMBL/GenBankTM (accession number AB723624). The
amino acid sequence of the light chain 22F6 was deduced from
the cDNA sequence and categorized in A3/A19 of subgroup II.
As mentioned above, the N-terminal amino acid sequence was
MDIVM, inwhichM (methionine)was adducted because of the
insertion of the nucleotide sequence of the restriction enzyme
NcoI site.
The deduced amino acid sequence was used for molecular
modeling. Structuremodels of the light chain were constructed
as shown in Fig. 2A. Amino acid residues Asp1 or Asp34, Ser27a,
and His27d are the candidate residues in the possible formation
of a catalytic triad-like structure. The distance betweenHis and
Ser is important. In a case of the catalytic triad of trypsin, theC
distance between His and Ser is 8.42 Å. That between His27d
and Ser27a in 22F6 light chain is 8.26 Å. By joining Asp1 or
Asp34, it might be preferable for constructing such a triad. The
amino acidsAsp1, Ser27a, andHis27d are identical to those of the
A18b germ line gene that were found, as previously reported, to
all possess amidase activity (16).
Cleavage Assays
The functions in most catalytic antibodies reported so far
were mostly investigated from the viewpoint of peptidase (1, 4,
20, 21), DNase (22–24), or RNase (25) activity. Therefore, in
this study, these three kinds of catalytic features were examined
as follows.
FIGURE 1. SDS-PAGE analysis of purified light chain. M, marker; 1, reduced
condition; 2, non-reduced condition. The purified light chain sample (250 ng)
was separated by 12% acrylamide gel electrophoresis and visualized by silver
staining. Under the non-reduced condition, the monomeric (26-kDa) and
dimeric (51- and 43-kDa) forms of 22F6 were observed. A weak band at 43 kDa
may be a different dimeric form from that of the band at 51 kDa. Under the
reduced condition, no other bands except for the 31 kDa band of the mono-
meric form were detected, indicating high purity.
FIGURE 2. Structure model for 22F6 light chain. A, side chains having the
potential to form serine protease-like triads (Asp1 (or Asp34), Ser27a, and
His27d) are shown. Asp, His, and Ser are colored red, blue, and green, respec-
tively. The distance between C of His27d and Ser27a is 8.26 Å, which is close to
the C distance (8.42 Å) between them in a catalytic triad of trypsin. B, Tyr32 is
visualized. The residue is situated between Asp34 and His27d and may be con-
cerned with the nuclease activity. Models for the light chain were visualized
using WebLab ViewerLite (Accelrys Inc., San Diego, CA).
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Hydrolysis of Synthetic Peptidyl Substrates (Amidase
Activity)—Amidase activity of 22F6 was investigated using syn-
thetic peptidyl-4-methyl-coumaryl-7-amide (MCA) substrates.
The results are shown in Fig. 3A. The light chain 22F6 cleaved
the peptide bond between Arg and MCA of Gln-Ala-Arg
(QAR)-MCA (which is mostly used as a trypsin-like substrate)
with a reaction velocity of 0.09m/h at the concentration of 4.0
M 22F6. For Glu-Ala-Arg (EAR)-MCA (factor Xa-like sub-
strate), it decomposed with the reaction velocity of 0.04 M/h.
The light chain hardly cleaved Glu-Lys-Lys (EKK)-MCA (plas-
min-like substrate), Arg (R)-MCA (trypsin-like substrate), Val-
Pro-Arg (VPR)-MCA (thrombin-like substrate), Lys (K)-MCA
(amino peptidase-like substrate), and Ala-Pro-Ala (APA)-
MCA (elastase-like substrate). Gabibov and co-workers (11)
obtained a catalytic antibody light chain (L12) showing a reac-
tion velocity of 0.03 m/h for cleavage of PFR-MCA at a con-
centration of 0.7 M L12.
The tendency of the amidase activity of the light chain 22F6
to cleave synthetic substrates differs considerably from that of
the other human light chains, such as chains 1, 6, 8, 10, 11, and
18, reported in a previous study (16). The 22F6 light chain
seems to possess an enzymatic feature partly of trypsin and
partly of factor Xa.
Hydrolysis of Phosphodiester Bonds
DNase Activity—DNase activity of the light chain 22F6 was
examined using pBR322 as the substrate.
As shown in Fig. 3B, 22F6 hydrolyzed the phosphodiester
bond of the plasmid, where 0 and 30 min of incubation of 22F6
with pBR322 were presented. In the case of 30 min of incuba-
tion, the bands of the nicked and the linear forms became
clearer, and the supercoiled form became fainter rather than
those of 0 min of incubation, indicating a weak DNase activity.
In this experiment, the hydrolysis did not take place without
magnesium ion in the reaction system.
A kinetic analysis of the hydrolysis of the plasmid was per-
formed under the following conditions: 20, 30, or 40 g/ml
plasmid, 10 g/ml light chain 22F6, and 30 min of incubation.
In the results, the reaction obeyed theMichaelis-Menten equa-
tion as shown in Fig. 3C, and the values of kcat and Km were
1.01  102/min and 4.36  107 M, respectively. These values
are comparable with those of Rodkey’s catalytic antibody, BV
04-01, in which kcat was 1.61  102/min and Km was 2.62 
108 M (24).
RNase Activity—In order to investigate RNase activity, we
extracted genomeRNAs from influenza virus andNoda virus in
accordance with past studies (17, 18). However, we failed to
prepare influenza virus RNA because it was very unstable. In
contrast, Noda virus RNAs (RNA-1 and RNA-2) were stable
and could be successfully prepared. The RNAs were submitted
to an RNase activity test using the light chain 22F6. The results
are shown in Fig. 3D. At lane 1, we can see two clear bands at
around 3.1 and 1.7 kb, which correspond to RNA-1 and RNA-2,
respectively. The RNA-1 disappeared at a concentration of 46.5
g/ml 22F6. At this concentration, several fragments generated
from the parent RNA-1 could be seen at around 1000, 760, and
630 kb (lane 4), which might be consecutively hydrolyzed from
the fragments at that concentration of 22F6. We could also see
FIGURE 3. Hydrolysis of peptide-MCA substrates and nucleic acids by
22F6 light chain. A, hydrolysis of peptide-MCA substrates. The 22F6 light
chain (5 M) was mixed with an equal volume of 50 M synthetic substrate
QAR-MCA (solid circle), EAR-MCA (open circle), EKK-MCA (solid triangle), VPR-
MCA (open triangle), K-MCA (solid square), or R-MCA (open square) and incu-
bated at 37 °C. QAR-MCA and EAR-MCA were cleaved with a turnover value of
0.018 and 0.007/h, respectively. B, hydrolysis of a phosphodiester bond of the
plasmid DNA pBR322. The 22F6 light chain inserted a nicked and a linear form
of the plasmid. The nicked form as well as the linear form became clearer, and
the supercoiled form became fainter at 30 min of incubation time. The hydrol-
ysis did not occur without magnesium ion. C, kinetic analysis. The decrease of
the supercoiled form obeyed the Michaelis-Menten equation (kcat  1.01 
102/min and Km  4.36  10
7
M). These values are comparable with those
of Rodkey’s catalytic antibody BV 04-01. D, cleavage of genome RNA from
Noda virus. Noda virus possesses RNA-1 and RNA-2. In lane 3, RNA-1 at 3.1 kb
(open arrow) disappeared at a concentration of 46.5 g/ml 22F6. In lane 4 (465
g/ml 22F6), several fragments (closed arrows) generated from the parent
RNA-1 could be observed at around 1,000, 760, and 630 kb. The cleavage was
dependent on the concentration of 22F6. M, marker. Lanes 1– 4, 0, 4.65, 46.5,
and 465 g/ml 22F6. Reaction conditions were as follows: Noda virus, 200 ng;
temperature, 25 °C; period, 24 h; volume, 20 l.
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a smear band below the RNA-2 band. The smear bandmight be
generated from RNA-2. The human catalytic light chain 22F6
has unique catalytic features capable of cleaving peptide bonds
as well as phosphodiester bonds.
Recognition Molecule of 22F6 in Influenza Proteins
The recognition molecule of the light chain 22F6 in proteins
of influenza virus type A (H1N1) was investigated by Western
blot analysis (Fig. 4), where a lysate of the virus was used. In this
experiment, 50.9 g/ml 22F6 was used, mostly employed at a
concentration below several g/ml. As already reported, the
subunit of the antibody lowered the affinity to the antigen by
about 1⁄100 in the heavy chain and 1⁄1,000 in the light chain,
although the recognition ability was not altered. A faint band
was identified at around 26 kDa, which corresponds to the HA2
domain of the hemagglutininmolecule located on the surface of
the virus, indicating that the light chain 22F6 could recognize
the hemagglutinin molecule with a low affinity.
In Vitro Assay; Neutralization Ability of 22F6 against Influenza
Viruses
The expressed andpurified light chain 22F6was submitted to
in vitro assays to examine the neutralization ability against both
influenza viruses H1N1 (A/Hiroshima/37/2001) and H3N2
(A/Hiroshima/71/2001). In general, it requires catalytic anti-
bodies for long term incubation (10–100 h) with its antigens
because of its low turnover values. In a previous study (15), we
reported that the preferable incubation temperature for a cat-
alytic antibody with influenza virus is 20 °C for an incubation
period of 48 h. Therefore, in this experiment, the human cata-
lytic light chain 22F6 (50 g/ml) was first incubated with 2,500
pfu/ml influenza virus H1N1 or H3N2 for 24 or 48 h at 25 °C,
and then the mixture was inoculated into the MDCK cell
monolayer (see “Materials and Methods”) to evaluate infectiv-
ity through the counting of the number of plaques on plates.
Fig. 5 shows the effect of the human light chain 22F6 on infec-
tion of influenza virus H1N1 or H3N2 in results where in vitro
assays were repeated twice. From the figure of the H1N1 virus
(left) at hour 24 of incubation, the catalytic light chain 22F6
showed little effect on the suppression of infectivity of the virus.
However, at hour 48 of incubation, the catalytic light chain
clearly suppressed infection of the H1N1 virus down to about
50% infectivity. On the other hand, in the case of the H3N2
virus, the effect of 22F6 was low at both 24 and 48 h of incuba-
tion compared with those of H1N1 virus.
In Vivo Assay; Survival Rate and Body Weight Changes of
BALB/c Mice
Weperformed an in vivo assay using BALB/cmice and influ-
enza virus H1N1 (PR-8 strain). The time course of negative
control mice (n  2 mice), which received nasal inoculation
without the influenza virus (50 l of PBS was given; mock
group), is shown in Fig. 6A. The time course of the body weight
of each mouse was normal, as shown in the graphs in the Fig.
6A. Photos of themicewere taken at 7 and 14 dpi. Their appear-
ance was also normal. No mice died in this negative control
experiment.
In Fig. 6B, an investigation of positive control mice infected
with intact influenza virus (50 l of PBS containing 1,000
pfu/50 l; positive control group) indicated that the body
weight of the four mice decreased until 7–9 dpi. All (four) mice
FIGURE 4. Western blot analysis for 22F6 light chain. Western blot of 22F6
light chain was performed against H1N1 virus proteins. A faint band was
identified at around 26 kDa, which corresponds to the HA2 domain of the
hemagglutinin molecule. The experiment used 50.9 g/ml 22F6, which sug-
gests that 22F6 had a lower affinity than a normal whole antibody. We could
detect only the band corresponding to HA2, indicating that 22F6 recognized
the hemagglutinin molecule.
FIGURE 5. In vitro assays. The human catalytic light chain 22F6 (50 g/ml)
was first incubated with 500 pfu plus 0.2 ml of influenza virus H1N1 or H3N2
for 24 or 48 h at 25 °C, and then the mixture was inoculated into the MDCK cell
monolayer. The experiments were repeated twice. Although the catalytic
light chain 22F6 showed little effect on the suppression of infectivity for both
influenza virus H1N1 and H3N2, the catalytic light chain clearly suppressed
infection of influenza virus H1N1 at 48 h of incubation. Error bars, S.D.
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exhibited decreases in body weight, and two of the four mice
died at 8 dpi (50% survival rate); the other twomicewere able to
survive and recovered their body weight by the final day (21
dpi).
The influenza virus was incubated with the catalytic light
chain 22F6 at 25 °C for 48 h, which was similar to the treatment
in the in vitro experiment. Then 50 l of the mixture was given
to mice via nasal inoculation (n  4 mice). The body weight
changes and survival rate of the mice were examined as shown
in Fig. 6C. One mouse decreased in body weight by 7 dpi but
recovered it after 12 dpi. The other three mice gradually
increased in body weight by 21 dpi. The appearance of the four
FIGURE 6. In vivo assays. A, negative control mice (n  2 mice) that received nasal administration without influenza virus (only PBS was given; mock group)
were examined as shown. The time courses of the body weight are presented in the top two graphs. The left graph shows the time course of the weight for each
mouse. The right graph shows the time course for the average body weight of two mice. The time courses of body weight were normal, as shown in the graphs.
Photographs of the mice were taken at 7 and 14 dpi. No abnormalities were observed. B, positive control mice infected with intact influenza virus (PR-8 strain)
were investigated. The body weight of four mice decreased until 7 dpi. All (four) mice exhibited decreases in body weight until 7 dpi. Two of the four mice died
at 8 dpi (50% survival rate), and the other two mice were able to survive and recover their body weight by the final day (21 dpi). The appearance of mouse 2 and
3 was abnormal. Their bodies became smaller, and their hair bristled up. C, effect of 22F6 catalytic light chain. Influenza virus H1N1 (PR-8 strain) was incubated
with the catalytic light chain 22F6 at 25 °C for 48 h, and then 50 l of the mixture was given to mice (BALB/cN Sea mice, 6 weeks old, female) via nasal
administration (n  4 mice). One mouse decreased in body weight by 7 dpi but recovered it after 12 dpi. The other three mice increased in body weight by 21
dpi. No mice died during the assay. The human catalytic light chain 22F6 exhibited a huge effect against influenza virus infection even in the in vivo assay. Error
bars, S.D.
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mice, judging from the photos taken at 7 and 14 dpi, reveals that
the mice were normal. Note that no mice died even at 21 dpi in
this experiment. The catalytic light chain 22F6 obviously
improved the survival rate as well as the loss of body weight.
Dose dependence of 22F6 was also investigated, as shown in
Fig. 7. In the experiment, the virus in nasal inoculation was
increased from 1,000 to 2,000 pfu/50 l in order to clearly
ascertain the differences. Incubation of 50 g/ml 22F6 with
influenza virus H1N1 did not show an effect (0% survival), but
that of 465 g/ml 22F6 substantially improved the survival rate
(65%) of the mice, indicating a clear dose dependence.
From an immunological point of view, we examined the anti-
body titer against influenza virus in themice serum tested in the
above in vivo assay (Fig. 6, A–C). In Fig. 8, the antibody titer
against the influenza virus is indicated on the vertical axis at 7,
14, and 21 dpi. The titer of control mice infected with intact
virus gradually increased, depending upon the time course
measured. At 21 dpi, the titer reached to 5,000-fold (vertical
axis). On the other hand, that of the mice infected with a solu-
tion including intact virus and 22F6 catalytic light chain was
2,500-fold at 21 dpi, which was significantly lower than that of
the control mice. This means that some part of the antigenicity
of the influenza virus was lost by contact with the catalytic light
chain 22F6. Mock mice inoculated with only PBS did not show
any response. These data indicate that the human light chain
22F6 possesses the ability to suppress infection of influenza
virus H1N1 (PR-8 strain) in vivo.
Investigation of Toxicity of Human Light Chain
Acute toxic features of the human light chain were
investigated.
Single-dose Inoculation—The oral and intraperitoneal inoc-
ulations of themice (n 3) consisted of 33.2 and 49.8 g/kg/day,
respectively. No abnormal findings were observed in these two
experiments. The intravenous inoculation (inoculation vol-
ume  15 ml/kg/day) was made up of, in detail, injections at
several concentrations, including 8.3, 24.9, 49.8 (1.66 mg/ml),
and 145.1 (9.67 mg/ml) mg/kg/day. For all of the single-dose
inoculations, nothing particularly noteworthy was observed at
all from the viewpoints of body weight, death rate (0%), and
dissection of the cranial, intrathoracic, and abdominal cavities
and lymph nodes of the mice in addition to their appearance.
The time course of the body weight of mice intravenously inoc-
ulated with 145.5 mg/kg is shown in Fig. 9, where no significant
differences were observed between the inoculated and control
mice (n  3 mice for each group).
Multiple-dose Inoculation—Multiple doses of 8.3 mg/kg
were given to mice (n  3) by intravenous inoculation of 8.3
mg/kg (inoculation volume  5 ml/kg, 1.66 mg/ml) every 7
days. No remarkable appearance or occurrences were observed
in body weight, food and water intake, and dissection. The
weight of each organ was measured, and no unusual findings
were observed. The brain, thymus, heart, lung, liver, kidney,
adrenal gland, and spleen were compared between non-inocu-
lated and inoculatedmice. In observations from this dissection,
we could not detect any abnormal occurrences (data not
shown).
DISCUSSION
In the last 2 decades, many functional catalytic antibody light
chains have been reported worldwide by many researchers
(26–30). Past studies point out that the active site of a catalytic
antibody resides in the variable region of the antibody and not
in the constant region (1, 20, 31). Catalytic antibody light
chains, such as an anti-vasoactive intestinal peptide antibody
light chain (1, 26), i41SL1–2 light chain (cleaving small pep-
tides) (32), ECL2B-2 light chain (cleaving CCR-5 peptide) (13),
and UA15 light chain (cleaving urease of H. pylori) (14) have
three identical amino acids (Asp1, Ser27a, and His93). Ueda and
co-workers (33) revealed the important role of the residues of
the three amino acids in a light chain exhibiting amidase activ-
ity by geneticallymutating the residues, using theirmouse anti-
body light chain. Uda and Hifumi (20) have already proposed,
using molecular modeling for 128 mouse -type germ line
genes, that the catalytic sites composed of Asp, Ser, and His in
mouse light chains are mostly encoded in certain particular
germ line genes, such as bd2, bb1, cr1, bl1, cs1, and bj2. Based on
the above concept applied to human cases, V germ line genes,
such asA3/A19,A5,A17,A18, andA23 of subgroup II of human
light chains, were considered to correspond to the mouse germ
FIGURE 7. Dose dependence. The dose dependence of 22F6 was investigated. In this experiment, the virus at 2,000 pfu/50 l was employed. Administration
of 50 g/ml 22F6 did not show an effect (0% survival), but that of 465 g/ml 22F6 substantially improved the survival rate (65%) of the mice.
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line genes. In our previous work (16), catalytic light chain 18,
which belongs to the A18 germ line gene, showed an ability to
suppress the infection of rabies virus both in vitro and in vivo. In
this study, we were able to successfully obtain the highly puri-
fied catalytic light chain 22F6, possessing interesting catalytic
features, which was prepared from human B-lymphocytes.
Regarding amidase activity, the light chain 22F6 cleaved the
synthetic peptidyl substrates of QAR-MCA and EAR-MCA
with a reaction rate (kcat value) comparable with that of light
chain 18 (12), but it did not cleaveVPR-MCAand EAR-MCAat
all, which have very different characteristics from light chain 18
reported previously (16). In addition, 22F6 possesses an ability
to insert a nick into pBR322 and convert to a linear form
through successive hydrolysis of phosphodiester bonds.
Kinetic parameters reported for catalytic antibodies showing
amidase, peptidase, DNase, and RNase activity are summarized
in Table 1, in which several forms of catalytic antibodies, such
as light chain alone, scFv, IgG, and pIgG, are listed. Regardless
of either synthetic peptides or nucleic acids as the substrate,
most catalytic antibodies have aKm value in the range of 103 to
105 M and a kcat value from 103 to 1.0 min1. 22F6 in this
study showed a cleaving velocity (V) similar to that of the L12
light chain. Regarding DNase or RNase activity, 22F6 showed
DNase activity comparable with that reported by Rodkey et al.
(24) (BV 04-01 antibody). In both Rodkey’s and our cases, mag-
nesium ion was necessary. Because 22F6 cleaved Noda virus
RNA (Fig. 3D), it is characteristic that 22F6 showed both ami-
dase and nuclease activity.
Rodkey’s catalytic antibody (BV 04-01) forms a catalytic site
composed of His27d and Tyr32 in a light chain. In the case of
22F6 light chain, the two amino acids are present at positions
identical to those of Rodkey’s catalytic antibody. In Fig. 2B,
Tyr32 situates between His27d and Asp34 in CDR-1 of 22F6.
His27d may be involved in the formation of both the nuclease
and amidase active sites. Thus, it is conceivable that the DNA
and RNA cleaving site (His27d and Tyr32) may co-exist with the
active site as amidase (Asp1 (or Asp34), Ser27a, His27d) in 22F6.
Namely, two different active sites may be present in one light
chain, although it is reported that the heavy chain is concerned
with the binding to DNA (40).
There have been many reports with respect to the structure
of catalytic site in antibody or its subunits. Kolesnikov et al. (41)
found a dyad structure, where the anti-idiotypic mAb (9A8)
displays esterolytic activity. Both the His35 and Ser99 residues
reside in the heavy chain and act as the catalytic site. The dyad
structure is not a special case. For instance, a signal peptidase
forms the dyad catalytic site composed of amino acid residues
(Ser90–Lys145) to cleave the peptide bond of a signal peptide
(42). Recently, Smirnov et al. (11) proposed a unique catalytic
antibody named the “reactibody,” which was prepared by
employing an innovative idea and technique. The A17 could
cleave paraoxon, where tyrosine positioned at 37 in the light
chain was mainly concerned with the enzymatic function).
FIGURE 8. Serum titer. The antibody titer against influenza virus in the mice serum tested in the above in vivo assay was examined. The titer of control mice
infected with intact virus gradually increased, depending upon the time course measured. At 21 dpi, the titer reached 5,000-fold, whereas mock mice
inoculated with only PBS did not show any response. On the other hand, the titer of the mice infected with a solution including intact virus and 22F6 catalytic
light chain was 2,500-fold at 21 dpi, which was significantly lower than that of the positive control mice. This means that some part of the antigenicity of the
influenza virus was lost by contact with the catalytic light chain 22F6.
FIGURE 9. Acute toxicity tests. The time courses of the body weight of mice
administered 145.5 mg/kg at single dose are shown. No significant differ-
ences between the administered (●) and control (E) mice were observed.
Error bars, S.D.
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Anyhow, it seems that some amino acids in CDR-1 in light
chain are often concerned with the formation of catalytic site.
Note that precise analysis of a three-dimensional structure of
a catalytic light chain is not the primary purpose of this work.
Rather, the purpose is to find potent light chain candidates and
then investigate their biological features.
In an in vitro assay, the catalytic light chain 22F6 was able to
substantially suppress infection of influenza virus H1N1. Incu-
bation was more effective after 48 h than 24 h. This means that
22F6 took the time to perform this function.On the other hand,
the monoclonal antibody C179 (which is a well known neutral-
izing antibody againstH1N1) did not show suchdependence on
incubation time. The monoclonal antibody completed binding
with the antigen within a short time. In contrast, a huge
dependence on incubation time was observed in the case of the
catalytic light chain 22F6, suggesting that 22F6 was working as
an enzyme in addition to binding to the antigen, followed by
degradation of influenza virus protein or RNA.
Note that the catalytic light chain 22F6 obviously improved
the survival rate as well as the body weight of mice when the
catalytic light chain was coinfected with influenza virus. Fig. 8
presents the important finding that the catalytic light chain
mustmake the antigenicity of theH1N1 virus decrease through
a catalytic feature of the light chains. The relationship between
such catalytic features and the ability to suppress influenza
virus infection is still unclear. However, based on the above
findings of enzymatic activity, binding to the hemagglutinin
molecule, decrease of the antigenicity of influenza virus, and
hydrolysis of Noda virus RNA1, there must be two possibilities
for 22F6 to possess anti-virus activity. One is the degradation of
the hemagglutinin molecule present on the surface membrane
of the virus. Another is the decomposition of genome RNA of
the virus, in which 22F6 penetrates the virus membrane and
enters into the virus.We assayed the degradation of the hemag-
glutininmolecule by 22F6.However, the degraded fragments of
the hemagglutinin molecule were hardly observed. In contrast,
the genome RNA (RNA-1) of Noda virus was clearly decom-
posed by 22F6, suggesting that 22F6 could possess the ability to
cleave RNA of influenza virus. Actually, as the loss of infectivity
of the influenza virus took place, it is plausible that 22F6 could
degrade the RNA and reduce the antigenicity. This assumption
will be investigated in near future. Anyhow, it is characteristic
that 22F6 human catalytic light chain possesses the strong sup-
pression activity for the infection of influenza virus in vivo as
well as in vitro.
Through the above data and discussion, we should note the
potency of our immune system once again. The light chain,
such as 22F6, can be produced in our bodies. It became well
known that the free light chains released in our bodies play
important roles for such diseases of AIDS, allergies, etc. (43). In
the case of this study, it is plausible that free antibody light
chains produced and released into our bodies are advantageous
to our health. In conclusion, because we could not observe any
problems with antibody light chains in acute toxicity tests, the
effective catalytic light chain holds huge potential as a new drug
for patient therapies in the future.
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